

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 142 996 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
**10.10.2001 Bulletin 2001/41**

(51) Int Cl.<sup>7</sup>: **C12N 15/08, C07K 16/18,  
C12N 5/12, C12P 21/08,  
G01N 33/53, G01N 33/577**

(21) Application number: **99959883.2**

(22) Date of filing: **17.12.1999**

(86) International application number:  
**PCT/JP99/07106**

(87) International publication number:  
**WO 00/37632 (29.06.2000 Gazette 2000/26)**

(84) Designated Contracting States:  
**DE FR GB**

(30) Priority: **22.12.1998 JP 36429598**

(71) Applicants:  
• **DAIICHI PURE CHEMICALS CO. LTD.**  
**Chuo-ku Tokyo 103-0027 (JP)**  
• **Miyazaki, Osamu**  
**Naka-gun, Ibaraki 319-1112 (JP)**  
• **Fukamachi, Isamu**  
**Naka-gun, Ibaraki 319-1112 (JP)**

(72) Inventors:  
• **MIYAZAKI, Osamu**  
**Daiichi Pure Chemicals Co., Ltd.**  
**Naka-gun, Ibaraki 319-1112 (JP)**  
• **FUKAMACHI, Isamu**  
**Daiichi Pure Chemicals Co., Ltd.**  
**Naka-gun, Ibaraki 319-1112 (JP)**

(74) Representative: **Hartz, Nikolai, Dr. et al**  
**Tal 29**  
**80331 München (DE)**

(54) **MONOCLONAL ANTIBODY AGAINST APOLIPOPROTEIN A-I**

(57) The present invention is drawn to a monoclonal antibody reacting specifically with (1) apoA-I occurring in HDL containing no apoA-II and having a molecular weight of 150,000 or less; and (2) apoA-I not binding to a lipid; a hybridoma producing this antibody; a method

of immunologically assaying apoA-I characterized by reacting the antibody with a specimen; and an assay reagent for apoA-I which contains the antibody. The invention realizes measurement of a specific apoA-I, which provides a novel index of lipid metabolism disorder, etc.

**EP 1 142 996 A1**

## Description

## Technical Field

5 [0001] The present invention relates to a monoclonal antibody against a specific human apolipoprotein A-I (hereinafter referred to as "apoA-I"); a method of immunologically assaying a specific apoA-I by use of the antibody; and an immunological assay reagent containing the antibody.

## Background Art

10 [0002] ApoA-I is a predominant apoprotein that constitutes HDL and plays an important role in reserve cholesterol transportation from peripheral cells to the liver (Philips M. C. *et al.*, *Biochem. Biophys. Acta*, 906: p. 223 (1987)). Therefore, apoA-I assay is performed in the diagnosis of arteriosclerosis.

15 [0003] In recent years, researchers have elucidated that an HDL containing apoA-I but containing no apolipoprotein A-II (hereinafter referred to as "apoA-II") (Ishizuka *et al.*, *"Igaku to Yakugaku,"* Vol. 39, No. 5, p. 1041, 1988) exhibits a stronger effect of pulling cholesterol from cells as compared with an HDL containing both apoA-I and apoA-II, and that an apoA-I not binding to a lipid and an apoA-I which is in the form of small particles and occurs in pre $\beta$ 1-HDL containing a small amount of lipid (T. Miida *et al.*, *Biochemistry*, 29: p. 10469 (1990)) play an important role in reverse cholesterol transport system from cells. Accordingly, assaying these specific apoA-I's is of increased importance.

20 Among HDLs containing apoA-I but containing no apoA-II, pre $\beta$ 1-HDL pulls cholesterol from peripheral cells through interaction specific to the cell surface (Fielding, C. *et al.*, *Lipid Res.*, 36: p. 211-228 (1995)), and its action is more effective than that of HDL. Thus, pre $\beta$ 1-HDL is particularly attracting researchers' attention.

25 [0004] However, since no antibody that selectively reacts with a specific apoA-I has been found, the target apoA-I must be isolated from other apoA-I's through a method such as electrophoresis or immune precipitation. Thus, a specific apoA-I cannot be assayed in a simple manner.

## Disclosure of the Invention

30 [0005] In view of the foregoing, the present inventors have carried out extensive studies and have successfully obtained a monoclonal antibody which specifically reacts with a certain species of apoA-I. The inventors have found that, by use of the monoclonal antibody, apoA-I's such as the aforementioned apoA-I not binding to a lipid and apoA-I composing pre $\beta$ 1-HDL can be assayed accurately in a simple manner, thereby enabling more accurate diagnosis of lipid metabolism disorder to be performed. The present invention has been accomplished on the basis of this finding.

35 [0006] Accordingly, the present invention provides a monoclonal antibody reacting specifically with (1) an apoA-I occurring in HDL which contains no apoA-II and has a molecular weight of 150,000 or less and (2) an apoA-I not binding to a lipid.

[0007] The present invention also provides a hybridoma for producing the monoclonal antibody.

[0008] The present invention also provides a method of immunologically assaying apoA-I, characterized by reacting the monoclonal antibody with a specimen.

40 [0009] Furthermore, the present invention provides a reagent for assaying an apoA-I containing the monoclonal antibody.

## Brief Description of the Drawings

45 [0010] Fig. 1 shows western blotting profiles (electrophoresis) indicating the specificity of the antibody of the present invention. Fig. 2 is a graph showing the specificity of the antibody of the present invention as obtained by ELISA. Fig. 3 contains graphs showing reactivity of the antibody of the present invention to fractions obtained through gel filtration. Fig. 4 shows two-dimensional electrophoresis profiles showing the specificity of the antibody of the present invention. Fig. 5 is a graph showing dilution proportionality of the antibody of the present invention during ELISA. Fig. 6 contains

50 charts showing the results of pre $\beta$ 1-HDL level assay on clinical specimens. Fig. 7 shows the pre $\beta$ 1-HDL levels as determined after heating of the clinical specimens. Fig. 8 shows percent decreases in pre $\beta$ 1-HDL level of clinical specimens after heating.

## Best Modes for Carrying Out the Invention

55 [0011] The monoclonal antibody of the present invention can be produced, for example, in the following manner.

[0012] Purified apoA-I or a lipoprotein containing apoA-I is used as an immunogen. No particular limitation is imposed on the animals for immunization, and animals such as mice and rats are generally used. Immunization can be performed

through a routine method. For example, there may be employed a method in which a suspension of an immunogen in a commonly employed buffer or physiological saline, or a mixture of the suspension and a replenisher such as the complete Freund's adjuvant is administered to an animal subcutaneously, intracutaneously, or intraperitoneally so as to perform primary immunization, and the immunization is repeated in accordance with needs. The administration dose of the immunogen—appropriately determined depending on the route of administration and the species of animal—is typically controlled to approximately 10 µg to 1 mg per administration. The immunocompetent cells to be used for cell fusion are preferably spleen cells collected 3-4 days after completion of immunization. Myeloma cells that serve as parent cells to be fused with the aforementioned immunocompetent cells may be of any known cell line that has already been established. Examples of the cell line include mouse cell lines such as NS1 (P3/NSI/I-Ag4444-1) [*Eur. J. Immunol.* 6:511-519 (1976)]; SP2/O-Ag14 [*Nature* 276:269 (1978)]; P3X63-Ag8.653 [*J. Immunol.* 123:1548 (1979)]; and P3X63-Ag8U.1 [*Curr. Top. Microbiol. Immunol.* 81:1 (1978)] and rat cell lines such as Y3-Ag1.2.3 [*Nature* 277:131-133 (1979)]; YB2/O (YB2/3HLP2.G11.16Ag.20) [*Methods Enzymol.* 73B:1 (1981)], and any of these can be used. In order to perform cell fusion, typically employed poly(ethylene glycol) (PEG), Sendai virus (HVJ), or a similar material can be used. Cell fusion may be performed in a typically employed manner. Specifically, immunocompetent cells are used in a total amount of approximately 1-10 times the amounts of the bone marrow cells, and poly(ethylene glycol) having an average molecular weight of 1,000-6,000 is used at a concentration of 30-60%. Poly(ethylene glycol) is added dropwise to pellets formed of a mixture of the immunocompetent cells and the bone marrow cells, and the resultant mixture is mixed. The target hybridoma may be selected by use of a typical culture medium such as an HAT medium (i.e., a medium containing hypoxanthine, aminopterin, and thymidine).

[0013] After completion of culturing in the HAT medium, the yielded hybridoma is subjected to typical limiting dilution analysis for retrieval of a target-antibody-producing strain and obtaining a monoclonal. In the retrieval of the target-antibody-producing strain, ELISA, RIA, or a similar assay can be employed, whereby a hybridoma producing an antibody which reacts specifically with a specific apoA-I can be selected.

[0014] The monoclonal antibody of the present invention may be selected through a method as described below.

[0015] Firstly, monoclonal antibodies contained in the supernatant of the culture medium are immobilized by use of an immobilizer such as an anti-mouse-IgG antibody, and, subsequently, a lipoprotein-containing mixture such as blood plasma is caused to react. Next, an anti-apoA-I antibody labeled with a labeling agent such as an enzyme or a similarly labeled antibody against apoA-II is caused to react, to thereby select a monoclonal antibody which reacts specifically with the anti-apoA-I antibody system but does not react with the anti-apoA-II antibody system.

[0016] Examples of the hybridoma producing such a monoclonal antibody include hybridoma 55201, which the present inventors previously found. Hybridoma 55201 was deposited as FERM BP-6938 (original depository date: 1998/11/17) to the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (address: 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki 305-8566 JAPAN).

[0017] The target antibody is produced from the thus-produced antibody-producing hybridoma by means of culturing the hybridoma in a routine manner and separating the antibody from the culture supernatant. Alternatively, the target antibody is obtained by administering the aforementioned hybridoma to a mammal adaptable to the hybridoma and collecting the antibody from ascites.

[0018] Monoclonal antibody 55201 produced by hybridoma 55201 is endowed with the following properties:

(A) to react with (1) an apoA-I occurring in HDL which contains no apoA-II and has a molecular weight of 150,000 or less and (2) an apoA-I not binding to a lipid, and

(B) to react with an apoA-I contained in ultracentrifugal fractions of HDL3 and bottom when blood plasma taken from a healthy human is fractionated by means of an ultracentrifuge into five fractions; i.e., VLDL, LDL, HDL2, HDL3, and bottom.

[0019] In the aforementioned (A), pre $\beta$ 1-HDL is particularly preferred as the (1) HDL which contains no apoA-II and has a molecular weight of 150,000 or less.

[0020] By use of the aforementioned antibody, a specific apoA-I contained in a human specimen can be assayed through any conventional immunological assay method. Blood plasma or blood serum is used as the specimen. Examples of the employable immunological assay method include RIA, EIA, and similar methods performed on the basis of a conventional competition method or sandwich method. When these methods are employed, a labeled antibody of the present invention may also be used. Examples of the substance for labeling include enzymes such as peroxidase, alkaline phosphatase, glucoamylase, and  $\beta$ -galactoxidase, and radioactive substances such as  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and tritium. Examples of supports for immobilizing the antibody include a variety of plastic wells and plastic beads.

[0021] When assay is performed by ELISA, purified apoA-I is used as a standard, and quantification can be performed in the following manner. Specifically, a diluted sample is added to an ELISA plate onto which the monoclonal antibody of the present invention is immobilized, to thereby cause reaction. Subsequently, an enzyme-labeled anti-apoA-I polyclonal antibody is caused to react to develop color, and apoA-I contained in the sample is quantitatively determined

based on the change in absorbance.

[0022] Similar to the case of a typical immunological assay, these assays can be performed at any temperature within 0-40°C.

[0023] As described above, the aforementioned (A) apoA-I (1) and/or apoA-I (2) contained in blood plasma or blood serum can be assayed by use of the monoclonal antibody of the present invention. However, assay values of specimens heated at 37°C are considerably low as compared with those non-heated. This indicates that the concentration of the aforementioned (A) apoA-I in blood plasma or blood serum lowers by heating at 37°C. Accordingly, the aforementioned (A) apoA-I contained in a specimen can also be assayed on the basis of this property. Specifically, the aforementioned (A) apoA-I is assayed through the aforementioned immunological assay method before and after heating the specimen, and the percent decrease, or amount of reduction, in assayed value attributable to heating is measured. Thus, the aforementioned (A) apoA-I can also be assayed. The temperature of the specimen is preferably 0-25°C before heating and 30-40°C after heating. Specimens before heating also include a specimen stored at a temperature as low as 0-10°C.

[0024] By employment of these assay methods, the aforementioned (A) apoA-I (1) and/or apoA-I (2) contained in blood plasma or blood serum can be assayed accurately in a simple manner.

#### Examples

[0025] The present invention will next be described in more detail by way of examples, which should not be construed as limiting the invention thereto.

#### Example 1 (Preparation of monoclonal antibody)

##### (1) Preparation of hybridoma

[0026] Pooled serum of a healthy human was ultracentrifuged, to thereby separate HDL, and the separated HDL was defatted by use of an ethanol-ether mixture and ether. After ether had been completely removed by nitrogen gas, the residue was re-dissolved in an 8M urea solution. The resultant solution was subjected to gel filtration by use of a Sephacryl S200 column (product of Pharmacia). From among separated fractions, fractions containing apoA-I were collected, and the mixture was dialyzed against PBS, to thereby obtain an immunogen. This immunogen and complete Freund's adjuvant (product of GIBCO) were admixed at 1 : 1, to thereby prepare a 0.1 mg/0.1 ml emulsion. The emulsion was subcutaneously administered to a 6-week old female BALB/C mouse six times at one-week intervals. Two days after completion of final immunization, the spleen was extirpated. Spleen cells obtained from the extirpated spleen and myeloma cells SP2/O-Ag14 were mixed at 6 : 1, and two cell species were fused in the presence of 50% polyethylene glycol 1540 (product of Wako Pure Chemical Industries, Ltd.). The thus-fused cells were suspended in an HAT medium such that the cell concentration was controlled to  $2.5 \times 10^6$ /mL as reduced to spleen cells. The suspension was poured into a 96-well culture plate (product of Corning) at 0.2 mL/well, followed by culturing at 37°C in a 5%CO<sub>2</sub> incubator. After approximately two weeks, a candidate antibody-producing strain was selected, through the ELISA method described hereunder, from a culture supernatant occurring in wells in which hybridoma had been grown. Briefly, IgG contained in each culture supernatant was immobilized on a microplate (product of Nunc) by the mediation of a goat anti-mouse IgG (Fc) antibody (product of Jackson). To the IgG-immobilized plate, a diluted plasma liquid of a healthy human was added so as to cause reaction of a lipoprotein (predominantly containing HDL) containing apoA-I. Subsequently, there was reacted a biotin-labeled anti-apoA-I antibody which had been prepared by biotinylating, with biotin-N-hydroxysuccinimide (product of Zymed), a goat anti-apoA-I antibody obtained by immunization of a goat with apoA-I or a biotin-labeled anti-apoA-II antibody which had been prepared by similarly biotinylating a goat anti-apoA-II antibody obtained by immunization of a goat with apoA-II. Further, peroxidase-labeled streptavidin (product of Zymed) was added for reaction. After these reactions were complete, the resultant product was allowed to develop color with a substrate solution containing o-phenylenediamine (product of Tokyo Kasei). The degree of coloring was measured by means of a microplate reader (A. 492), to thereby select strains which exhibited high reactivity in the system employing the biotin-labeled anti-apoA-I antibody but exhibited no reactivity in the system employing the biotin-labeled anti-apoA-II antibody. The thus-obtained hybridoma was cloned through limiting dilution, to thereby prepare monoclonal antibody hybridoma 55201.

##### (2) Preparation of monoclonal antibody

[0027] To each of 12-week old female BALB/C mice to which pristane (0.5 mL) had been intraperitoneally injected in advance, hybridoma 55201 (cells  $0.5 \times 10^6$ ) was intraperitoneally administered two weeks after the above injection of pristane. About 14 days after administration of the hybridoma, ascites was collected and centrifuged, to thereby

yield a supernatant. The supernatant was admixed with an equi-amount of a buffer for adsorption (3M NaCl-1.5M glycine-NaOH, pH 8.5), and the mixture was filtered. The resultant filtrate was passed through a protein A column (product of Pharmacia) which had been equilibrated with the buffer for adsorption, to thereby adsorb the antibody onto the column. The adsorbed antibody was eluted by use of a 0.1M citric acid buffer (pH 3.0), to thereby purify the monoclonal antibody 55201.

## Example 2 (Specificity of monoclonal antibody)

### (1) Western blotting

**[0028]** In order to confirm that the antibody obtained in Example 1 is in fact an antibody against apoA-I, the antibody was analyzed through western blotting. Specifically, blood serum of a healthy human was subjected to SDS-polyacrylamide gel electrophoresis, and the separated matter was electrically transferred to a PVDF membrane (product of Millipore). The transferred matter was blocked for one hour with PBST (PBS supplemented with 0.05% Tween 20) containing 3% skim milk. Subsequently, the monoclonal antibody 55201 and peroxidase-labeled anti-mouse IgG antibody (product of American Qualex) were reacted as a primary antibody and a secondary antibody, respectively. After the PVDF membrane had been washed with PBST, diaminobenzidine was added as a substrate, to thereby allow to develop color. As shown in Fig. 1, the monoclonal antibody 55201 exhibited a unique band corresponding to an apoA-I of a molecular weight of 28,000, confirming that the antibody is an antibody specific for apoA-I.

### (2) ELISA

**[0029]** The monoclonal antibody (55201) obtained in Example 1 was diluted with 20mM phosphate buffered saline (PBS; pH 7.2), to thereby adjust the concentration to 3 µg/mL. The diluted antibody was added to a 96-well ELISA plate (product of Nunc) at 50 µL/well and incubated at 4°C for one night. The plate was washed three times with PBS, and, subsequently, a blocking liquid (PBS containing 1% BSA) was added at 100 µL/well, to thereby carry out blocking for one hour. After removal of the blocking liquid, blood plasma of a healthy human diluted by the blocking liquid was added at 50 µL/well, and incubation was carried out for one hour at room temperature. The plate was washed three times with the blocking liquid, and, subsequently, a biotin-labeled goat anti-apoA-I antibody or a biotin-labeled anti-apoA-II antibody was added at 50 µL/well, and incubation was carried out for one hour at room temperature. In a similar manner, the plate was washed three times with the blocking liquid, and, subsequently, peroxidase-labeled streptavidin was added, followed by incubation for 30 minutes at room temperature. The plate was washed again three times with the blocking liquid, and, subsequently, a peroxidase substrate solution was added at 50 µL/well. Ten minutes after addition of the substrate solution, 1.5N sulfuric acid was added at 50 µL/well, and absorbance at 492 nm was measured.

**[0030]** Fig. 2 shows the results. As is clear from Fig. 2, the monoclonal antibody 55201 does not react with HDL containing apoA-II, but reacts specifically with HDL containing apoA-I alone.

### (3) Reactivity with respect to fractions separated through gel filtration

**[0031]** In order to study the specificity of the antibody obtained in Example 1, blood plasma of a healthy human was separated through gel filtration, and the reactivity of the antibody to each separated fraction was investigated. Specifically, blood plasma of a healthy human was separated by means of a Pharmacia FPLC system in which four gel filtration columns (TSK-GEL G3000SW, 7.5 mmID × 60 cm (×2); G3000SW, 7.5 mmID × 30 cm (×1); and Pharmacia Superdex 200 HR10/30 (×1)) were connected. The apoprotein concentration of each fraction was measured and the reactivity of the monoclonal antibody to each fraction was compared through the below-described ELISA method. The monoclonal antibody 55201 obtained in Example 1 was diluted with 20mM phosphate buffered saline (PBS; pH 7.2), to thereby adjust the concentration to 3 µg/mL. The diluted antibody was added to a 96-well ELISA plate (product of Nunc) at 50 µL/well and incubated at 4°C for one night. The plate was washed three times with PBS, and, subsequently, a blocking liquid (PBS containing 1% BSA) was added at 100 µL/well, to thereby carry out blocking for one hour. After removal of the blocking liquid, each fraction diluted by the blocking liquid or purified apoA-I was added at 50 µL/well, and incubation was carried out for one hour at room temperature. The plate was washed three times with the blocking liquid, and, subsequently, a peroxidase-labeled goat anti-apoA-I antibody which had been obtained by labeling a goat anti-apoA-I antibody, yielded by immunizing a goat with apoA-I, through a periodic acid method, was added at 50 µL/well, and incubation was carried out for one hour at room temperature. In a similar manner, the plate was washed three times with the blocking liquid, and, subsequently, a peroxidase substrate solution was added at 50 µL/well. Ten minutes after addition of the substrate solution, 1.5N sulfuric acid was added at 50 µL/well, and absorbance at 492 nm was measured. Based on purified apoA-I as a standard, the amount of apoA-I in each fraction was calculated. The results are shown in Fig. 3 (lower). Each of apoproteins; i.e., apoA-I, apoA-II, and apo-E, was assayed through ELISA by use

of a polyclonal antibody obtained by immunizing a goat with each apoprotein and a peroxidase-labeled antibody thereof obtained through a periodic acid method. The results are shown in Fig. 3 (upper). As is clear from Fig. 3 (lower), the monoclonal antibody 55201 predominantly reacts specifically with an apoA-I contained in HDL which occurs in blood plasma and has a molecular weight of 67,000 or less, or with an apoA-I not binding to a lipid.

#### (4) Reactivity with respect to ultracentrifuged fractions

**[0032]** In order to study the specificity of the monoclonal antibody 55201 obtained in Example 1, blood plasma of a healthy human (30 mL) was separated by means of an ultracentrifuge (product of Hitachi) into five fractions; i.e., VLDL, LDL, HDL2, HDL3, and bottom, so as to determine which fraction contains particles reactive with the antibody 55201. Specifically, the amount of apoA-I in each separated fraction was measured through ELISA as employed in Example 2(3), with reference to purified apoA-I as a standard. Table 1 shows the results. As shown in Table 1, fractions VLDL, LDL, and HDL2 contain substantially no plasma component reactive with the monoclonal antibody 55201, and fractions HDL3 and bottom contain such a reactive plasma component. The results indicate that the antibody 55201 does not react with an apoA-I contained in a fraction of low specific gravity such as HDL2, but reacts with apoA-I contained in fractions of high specific gravity; i.e., HDL3 and bottom.

Table 1

Fractions	Specific gravity	apoA-I ( $\mu$ g) *
VLDL	<1.006	0
LDL	1.006-1.063	12
HDL2	1.063-1.125	24
HDL3	1.125-1.21	1296
Bottom	1.21<	1785

\* the amount of apoA-I in particles reactive with the antibody 55201

#### (5) Reaction with pre $\beta$ 1-HDL

**[0033]** In order to study the specificity of the monoclonal antibody 55201 obtained in Example 1, analysis through non-denaturing two-dimensional electrophoresis was carried out. Specifically, the monoclonal antibody 55201 or normal mouse IgG was added to blood plasma of a healthy human, and each sample was subjected to 0.75% agarose gel electrophoresis. A fragment was cut from the agarose gel, and the cut agarose gel fragment was subjected to polyacrylamide gel electrophoresis. The separated matter was electrically transferred to nitrocellulose membrane (product of Millipore) and reacted with a  $^{125}$ I-labeled goat anti-apoA-I antibody. The changes observed in the HDL subfractions were compared through autoradiography. The results are shown in Fig. 4. In contrast with the subfraction using a normal mouse IgG system serving as a control, spots attributed to pre $\beta$ 1-HDL disappeared and spots possibly corresponding to formation of a complex of IgG and pre $\beta$ 1-HDL in monoclonal antibody 55201-added system were observed, whereas spots attributed to HDLs other than pre $\beta$ 1-HDL were unchanged. The results indicate that the monoclonal antibody 55201 reacts specifically with pre $\beta$ 1-HDL.

#### (6) pre $\beta$ 1-HDL level after heating at 37°C

**[0034]** In order to study the specificity of the monoclonal antibody 55201 obtained in Example 1, blood plasma of a healthy human (0.2 mL) which had been stored at 4°C was poured into microtubes, followed by incubation at 37°C for two hours, to thereby investigate the effect on reactivity with the antibody. Specifically, the pre $\beta$ 1-HDL concentration in blood plasma was measured, before and after incubation, through ELISA as employed in Example 2(3) with reference to purified apoA-I as a standard. Table 2 shows the results. As is clear from Table 2, the reactivity lowers considerably after incubation at 37°C; i.e., the level of pre $\beta$ 1-HDL in blood is lowered by heating.

Table 2

	Level measured ( $\mu$ g/mL)	
	Before incubation	after incubation
Specimen 1	19.9	2.1
Specimen 2	20.1	2.7

Table 2 (continued)

	Level measured (µg/mL)	
	Before incubation	after incubation
Specimen 3	16.9	4.0
Specimen 4	20.7	5.0
Specimen 5	21.8	2.2

#### Example 3 (Method of measurement)

**[0035]** By use of the antibody obtained in Example 1, the pre $\beta$ 1-HDL concentration in human blood plasma (three specimens) was measured. Specifically, the pre $\beta$ 1-HDL concentration in human blood plasma was measured through ELISA as employed in Example 2(3) with reference to purified apoA-I as a standard. As shown in Fig. 5, all three specimens exhibit favorable dilution proportionality, indicating the feasibility of measuring the pre $\beta$ 1-HDL concentration.

#### Example 4 (Measurement of clinical specimens)

**[0036]** In order to study the clinical significance of pre $\beta$ 1-HDL measurement confirmed in Example 3, blood plasma specimens of 39 hyperlipidemia patients and blood specimens of 11 healthy humans were provided, with all specimens stored at 4°C. The pre $\beta$ 1-HDL concentration in each blood plasma specimen before and after heating at 37°C was measured through ELISA as employed in Example 2(3). In addition, as a control, the total apoA-I concentration in blood plasma—obtained through a conventional technique—was measured through immunoturbidimetry by use of blood plasma specimens before heating at 37°C.

**[0037]** Fig. 6 shows the total apoA-I concentration and pre $\beta$ 1-HDL concentration of blood plasma specimens before heating at 37°C. Although no clear difference was observed between the patients and healthy humans in terms of the total apoA-I concentration, considerable difference was observed between the patients and healthy humans in terms of the pre $\beta$ 1-HDL concentration.

**[0038]** Fig. 7 shows the pre $\beta$ 1-HDL concentration after heating. Considerable difference was observed between the patients and healthy humans in terms of the average pre $\beta$ 1-HDL concentration; i.e., 3.8 µg/mL for healthy humans and 12.2 µg/mL for the patients.

**[0039]** Fig. 8 shows the percent reduction of pre $\beta$ 1-HDL concentration before heating to that after heating. Considerable difference was observed between the patients and healthy humans in terms of the average percent reduction; i.e., 79.1% for healthy humans and 68.5% for the patients.

**[0040]** The above-described results indicate that measuring the pre $\beta$ 1-HDL concentration before and after heating and measuring reduction in the concentration after heating or the reduction ratio thereof provide useful indices showing lipid metabolism disorders.

#### Industrial Applicability

**[0041]** By use of the antibody of the present invention, which reacts specifically with a specific apoA-I, a specific apoA-I contained in human body fluid can be measured, providing a novel index for lipid metabolism disorder and the like.

#### Claims

1. A monoclonal antibody reacting specifically with (1) a human apolipoprotein A-I occurring in HDL which contains no human apolipoprotein A-II and has a molecular weight of 150,000 or less and (2) a human apolipoprotein A-I not binding to a lipid.
2. The monoclonal antibody as described in claim 1, wherein the HDL (1) which contains no human apolipoprotein A-II and has a molecular weight of 150,000 or less is pre $\beta$ 1-HDL.
3. A hybridoma for producing the monoclonal antibody as recited in claim 1 or 2.
4. An immunoassay method for a human apolipoprotein A-I, **characterized by** reacting the monoclonal antibody as recited in claim 1 or 2 with a specimen.

**EP 1 142 996 A1**

5. The method as described in claim 4, which is performed through RIA or EIA.
6. The method as described in claim 4 or 5, wherein measurement is performed before and after heating the specimen, and the amount of reduction or percent reduction after heating is determined.
7. A reagent for assaying a human apolipoprotein A-I containing the monoclonal antibody as recited in claim 1 or 2.
8. The reagent according to claim 7, which is for RIA or EIA.

5

10

15

20

25

30

35

40

45

50

55



FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7





FIG. 8





## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/07106

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> C12N 15/08, C07K 16/18, C12N 5/12, C12P 21/08, G01N 33/53, G01N 33/577		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N 15/08, C07K 16/18, C12N 5/12, C12P 21/08, G01N 33/53, G01N 33/577		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPI (DIALOG), BIOSIS (DIALOG)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Feilding CJ. et al.	1-2
Y	"Molecular physiology of reverse cholesterol transport", J.Lipid Research(1995), Vol.36 , No.2 , p.211-228	3-8
Y	Fielding PE. et al., "Unique epitope of apolipoprotein A-1 expressed in pre-beta-1 high-density lipoprotein and its role in the catalyzed efflux of cellular cholesterol", Biochemistry(1994), Vol.33 , No.22 , p.6981-6985	1-8
Y	Gursky O. et al., "Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state", Proc.Natl.Acad.Sci.USA(1996), Vol.93 , No.7 , p.2991-2995	6-8
PY	Sparks DL. et al., "Effect of apolipoprotein A-1 lipidation on the formation and function of pre-beta and alpha -migrating LpA-1 particles", Biochemistry(1999 Feb), Vol.38 , No.6 , p.1727-1735	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 13 March, 2000 (13.03.00)		Date of mailing of the international search report 21 March, 2000 (21.03.00)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)


## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/07106J

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Miida T. et al., "Mechanism of transfer of LDL-derived free cholesterol to HDL subfractions in human plasma", Biochemistry(1990), Vol.29 , No.46 , p.10469-10474	1-8
A	Bekaert ED. et al., "Competitive enzyme inhibition immunoassay of apolipoprotein A-1: use of monoclonal antibodies", Clin. Chem. (1988), Vol.34 , No.6 , p.1030-1035	1-8

Form PCT/ISA/210 (continuation of second sheet) (July 1992)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 142 996 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)

INID code(s) 71

(51) Int Cl.7: **C12N 15/08**, C07K 16/18,  
C12N 5/12, C12P 21/08,  
G01N 33/53, G01N 33/577

(48) Corrigendum issued on:

30.01.2002 Bulletin 2002/05

(86) International application number:

PCT/JP99/07106

(43) Date of publication:

10.10.2001 Bulletin 2001/41

(87) International publication number:

WO 00/37632 (29.06.2000 Gazette 2000/26)

(21) Application number: 99959883.2

(22) Date of filing: 17.12.1999

(84) Designated Contracting States:

DE FR GB

(30) Priority: 22.12.1998 JP 36429598

(71) Applicant: DAIICHI PURE CHEMICALS CO. LTD.

Chuo-ku Tokyo 103-0027 (JP)

• FUKAMACHI, Isamu  
Daiichi Pure Chemicals Co., Ltd.  
Naka-gun, Ibaraki 319-1112 (JP)

(74) Representative: Hartz, Nikolai F., Dr. et al  
Wächtershäuser & Hartz, Patentanwälte, Tal 29  
80331 München (DE)

(72) Inventors:

• MIYAZAKI, Osamu  
Daiichi Pure Chemicals Co., Ltd.  
Naka-gun, Ibaraki 319-1112 (JP)

(54) **MONOCLONAL ANTIBODY AGAINST APOLIPOPROTEIN A-I**

(57) The present invention is drawn to a monoclonal antibody reacting specifically with (1) apoA-I occurring in HDL containing no apoA-II and having a molecular weight of 150,000 or less; and (2) apoA-I not binding to a lipid; a hybridoma producing this antibody; a method

of immunologically assaying apoA-I characterized by reacting the antibody with a specimen; and an assay reagent for apoA-I which contains the antibody. The invention realizes measurement of a specific apoA-I, which provides a novel index of lipid metabolism disorder, etc.

EP 1 142 996 A8

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**